Skip to content

Prevention of Myocardial Dysfunction and Injury Resulting From Salter Innominate Osteotomy by Caudal Block

Prevention of Pro-inflammatory Cytokines-associated Myocardial Dysfunction and Injury Resulting From Salter Innominate Osteotomy by Caudal Block

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02144766
Enrollment
40
Registered
2014-05-22
Start date
2014-04-30
Completion date
2014-10-31
Last updated
2014-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Dysfunction, Myocardial Injury

Brief summary

The goal of the present study was to investigate the role of pro-inflammatory cytokines in myocardial dysfunction and injury resulting from noncardiac injury in children and whether or not anti-inflammatory treatment with caudal block prevents pro-inflammatory cytokines-associated myocardial dysfunction and injury following noncardiac surgery.

Interventions

DRUGropivacaine

caudal block with 1 ml/kg of ropivacaine 0.2%

DRUGsaline

caudal block with 1 ml/kg of saline

Sponsors

Si-Qin Chen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Years to 5 Years
Healthy volunteers
No

Inclusion criteria

* Children diagnosed for developmental dysplasia of the hip (DDH) undergoing Salter innominate osteotomy will be recruited into the study.

Exclusion criteria

* Children with anemia, electrolyte disturbances, abnormal acid-base status, bleeding diathesis, history of allergy to local anesthetics, neurologic and spinal diseases, skin infections on the caudal area, renal dysfunction, symptomatic cardiovascular and respiratory disease

Design outcomes

Primary

MeasureTime frame
change from baseline(before induction of anesthesia) in plasma concentrations of IL(interleukin)-6 at 72h after surgerybaseline(before induction of anesthesia), 72h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of TNF(tumor necrosis factor)-α at 48h after surgerybaseline(before induction of anesthesia), 48h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of TNF(tumor necrosis factor)-α at 72h after surgerybaseline(before induction of anesthesia), 72h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of IL(interleukin)-6 at arrival in the postanesthesia care unitbaseline(before induction of anesthesia), arrival in the postanesthesia care unit
change from baseline(before induction of anesthesia) in plasma concentrations of IL(interleukin)-6 at 3h after surgerybaseline(before induction of anesthesia), 3h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of IL(interleukin)-6 at 24h after surgerybaseline(before induction of anesthesia), 24h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of IL(interleukin)-6 at 48h after surgerybaseline(before induction of anesthesia), 48h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of NT(N terminal)-proBNP at arrival in the postanesthesia care unitbaseline(before induction of anesthesia), arrival in the postanesthesia care unit
change from baseline(before induction of anesthesia) in plasma concentrations of NT(N terminal)-proBNP at 3h after surgerybaseline(before induction of anesthesia), 3h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of NT(N terminal)-proBNP at 24h after surgerybaseline(before induction of anesthesia), 24h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of NT(N terminal)-proBNP at 48h after surgerybaseline(before induction of anesthesia), 48h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of NT(N terminal)-proBNP at 72h after surgerybaseline(before induction of anesthesia), 72h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of CK(creatine kinase)-MB at arrival in the postanesthesia care unitbaseline(before induction of anesthesia), arrival in the postanesthesia care unit
change from baseline(before induction of anesthesia) in plasma concentrations of CK(creatine kinase)-MB at 3h after surgerybaseline(before induction of anesthesia), 3h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of CK(creatine kinase)-MB at 24h after surgerybaseline(before induction of anesthesia), 24h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of CK(creatine kinase)-MB at 48h after surgerybaseline(before induction of anesthesia), 48h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of CK(creatine kinase)-MB at 72h after surgerybaseline(before induction of anesthesia), 72h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of cTn(troponin)I at arrival in the postanesthesia care unitbaseline(before induction of anesthesia), arrival in the postanesthesia care unit
change from baseline(before induction of anesthesia) in plasma concentrations of cTn(troponin)I at 3h after surgerybaseline(before induction of anesthesia), 3h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of cTn(troponin)I at 24h after surgerybaseline(before induction of anesthesia), 24h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of cTn(troponin)I at 48h after surgerybaseline(before induction of anesthesia), 48h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of cTn(troponin)I at 72h after surgerybaseline(before induction of anesthesia), 72h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of TNF(tumor necrosis factor)-α at arrival in the postanesthesia care unitbaseline(before induction of anesthesia), arrival in the postanesthesia care unit
change from baseline(before induction of anesthesia) in plasma concentrations of TNF(tumor necrosis factor)-α at 3h after surgerybaseline(before induction of anesthesia), 3h after surgery
change from baseline(before induction of anesthesia) in plasma concentrations of TNF(tumor necrosis factor)-α at 24h after surgerybaseline(before induction of anesthesia), 24h after surgery

Secondary

MeasureTime frame
change from baseline(just before the start of surgery) in MAP(mean arterial pressure) at 3h after surgerybaseline(just before the start of surgery), 3h after surgery
change from baseline(just before the start of surgery) in CVP(central venous pressure) at arrival in the postanesthesia care unitbaseline(just before the start of surgery), at arrival in the postanesthesia care unit
change from baseline(just before the start of surgery) in CVP(central venous pressure) at 3h after surgerybaseline(just before the start of surgery), 3h after surgery
change from baseline(just before the start of surgery) in HR(heart rate) at arrival in the postanesthesia care unitbaseline(just before the start of surgery), at arrival in the postanesthesia care unit
change from baseline(just before the start of surgery) in HR(heart rate) at 3h after surgerybaseline(just before the start of surgery), 3h after surgery
change from baseline(just before the start of surgery) in MAP(mean arterial pressure) at arrival in the postanesthesia care unitbaseline(just before the start of surgery), at arrival in the postanesthesia care unit

Countries

China

Contacts

Primary ContactSiQin Chen, MD
chensiqin1983@hotmail.com+8613918085974

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026